Animal derived antibodies should be considered alongside convalescent human plasma to deliver treatments for COVID-19

Abstract

Published data on the first 5,000 coronavirus patients to receive plasma shows promise in the United States. However, delivering convalescent plasma therapies in low- and even middle-income countries is both difficult and costly. Here we discuss the advantages and disadvantages of antisera raised in animals that may allow poorer countries to control the devastating effects of COVID-19.